Abstract 3407
Background
Few studies have directly investigated the differential expression of miRNA between low-tobacco and high-tobacco exposed HNSCC. The purpose of this study is to screen the differentially expressed miRNA and to investigate the clinical significance and potential biological mechanisms in above two groups of HNSCC.
Methods
The HNSCC datasets were obtained from TCGA database. Meanwhile, we collected 22 HNSCC patients in our hospital. The differentially expressed miRNAs between low-tobacco and high-tobacco exposed HNSCC were identified based on log2FC > 1 and FDR < 0.05. KM survival analysis, Cox regression, chi-square test were used to evaluate the clinical significance of miRNA. The correlation between gene and clinical characteristic was analyzed by WGCNA. TargetScan, miRDB, DIANA databases were used to predict the target genes of miRNA. RT-qPCR was used to identify miRNA expression in HNSCC tissues. p < 0.05 was considered statistically significant.
Results
30 differentially expressed miRNAs were identified between low-tobacco and high-tobacco exposed HNSCC. The patients with high expression of miR-499a had lower overall survival than those with low expression of miR-499a in high-tobacco exposed HNSCC (p = 0.02). Multivariate Cox regression showed that high expression of miR-499a was an independent risk factor for prognosis of high-tobacco exposed HNSCC (HR = 3.26, p = 0.03). Chi-square test showed that miR-499a was related to N stage in high-tobacco exposed HNSCC (p < 0.01). The clinical significance of miR-499a was not found in low-tobacco exposed HNSCC. WGCNA identified genes associated with N stage in high-tobacco exposed HNSCC. The three databases predicted the target genes of miR-499a, which intersected the genes associated with N stage. ZNRF1, AEBP2, NUS1 were obtained. RT-qPCR showed that miR-499a was differentially expressed between low-tobacco and high-tobacco exposed HNSCC in our own patients.
Conclusions
30 differentially expressed miRNAs are identified between low-tobacco and high-tobacco exposed HNSCC. In high-tobacco exposed HNSCC, highly expressed miR-499a may promote lymph node metastasis by down-regulating one or more of ZNRF1, AEBP2, NUS1, resulting in shortened patient survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract